A reply to "Correspondence Re: Development, validation and results from the impact of treatment evolution in non-small cell lung cancer (iTEN) model"
Lung Cancer
.
2021 Jan:151:110-111.
doi: 10.1016/j.lungcan.2020.11.015.
Epub 2020 Dec 2.
Authors
Daniel Moldaver
1
,
Manjusha Hurry
2
,
William K Evans
3
,
Parneet K Cheema
4
,
Randeep Sangha
5
,
Ronald Burkes
6
,
Barbara Melosky
7
,
Diana Tran
8
,
Darryl Boehm
9
,
Jaya Venkatesh
9
,
Susan Walisser
7
,
Erik Orava
2
,
Daniel Grima
10
Affiliations
1
Cornerstone Research Group, Burlington, Ontario, Canada.
2
AstraZeneca Canada, Mississauga, Ontario, Canada.
3
McMaster University, Hamilton, Ontario, Canada.
4
William Osler Health System, Brampton, Ontario, Canada.
5
Cross Cancer Institute, Edmonton, Alberta, Canada.
6
Mount Sinai Hospital, Toronto, Ontario, Canada.
7
BC Cancer, Vancouver, British Columbia, Canada.
8
Eversana Life Sciences Services, Burlington, Ontario, Canada.
9
Saskatchewan Cancer Agency, Regina, Saskatchewan, Canada.
10
Eversana Life Sciences Services, Burlington, Ontario, Canada. Electronic address: daniel.grima@eversana.com.
PMID:
33323299
DOI:
10.1016/j.lungcan.2020.11.015
No abstract available
Publication types
Letter
Comment
MeSH terms
Carcinoma, Non-Small-Cell Lung* / drug therapy
Humans
Lung Neoplasms* / drug therapy